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(57) ABSTRACT 
A method for fabricating a micro-organ device comprises 
providing a microscale support having one or more microf-
luidic channels and one or more micro-chambers for housing 
a micro-organ and printing a micro-organ on the microscale 
support using a cell suspension in a syringe controlled by a 
computer-aided tissue engineering system, wherein the cell 
suspension comprises cells suspended in a solution contain-
ing a material that functions as a three-dimensional scaffold. 
The printing is performed with the computer-aided tissue 
engineering system according to a particular pattern. The 
micro-organ device comprises at least one micro-chamber 
each housing a micro-organ; and at least one microfluidic 
channel connected to the micro-chamber, wherein the micro-
organ comprises cells arranged in a configuration that 
includes microscale spacing between portions of the cells to 
facilitate diffusion exchange between the cells and a medium 
supplied from the at least one microfluidic channel. 
6 Claims, 8 Drawing Sheets 
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MICRO-ORGAN DEVICE 
	
includes U.S. Pat. No. 5,612,188 issued to Shuler et al., which 
is hereby incorporated by reference. This patent discloses a 
	
CROSS REFERENCE TO RELATED 	 multi-compartmental cell culture system comprising culture 
APPLICATIONS 
	
	
chambers, sensors, and pumps, but is a system operating on a 
5 large scale, so the physiological parameters vary consider- 
The application claims the benefit of U.S. Provisional 	 ably from those found in an in vivo situation. 
Application Ser. No. 60/908,918, filed on Mar. 29, 2007. This 	 The related art also includes U.S. Pat. No. 7,288,405 by 
provisional application is incorporated herein by reference in 	 Shuler et al., which is incorporated herein by reference. This 
its entirety. 	 reference discloses in vitro microscale cell culture analog 
10 devices that permit cells to be maintained in vitro under 
ORIGIN OF INVENTION 	 conditions similar to those found in vivo. The microscale 
culture device comprises a fluidic network of channels seg- 
The invention described herein was made in the perfor- 	 regated into discrete but interconnected chambers. The spe- 
mance of work under a NASA contract and is subject to 	 cific chamber geometry is designed to provide cellular inter- 
Public Law 96-517 (35 U.S.C. §200 et seq.). The contractor 15 actions, liquid flow, and liquid residence parameters that 
has not elected to retain title to the invention. The invention 	 correlate with those found for the corresponding cells, tis- 
described herein was also made by employee(s) of the United 	 sues, or organs in vivo. Fluidics are designed to accurately 
States Government and may be manufactured and used by or 	 represent primary elements of the circulatory or lymphatic 
for the Government of the United States of America for gov- 	 systems. In one embodiment, the components are integrated 
ernmental purposes without the payment of any royalties 20 into a chip format. The design and validation of these geom- 
thereon or therefor. 	 etries is based on a physiological-based phannacokinetic 
(PBPK) model, a mathematical model that represents the 
	
BACKGROUND OF INVENTION 	 body as interconnected compartments representing different 
tissues. 
1. Field of Invention 	 25 	 Similarly, U.S. Patent Application Publication No. 2003/ 
The invention relates generally to devices for testing of 	 0152909 Al discloses micro-organ cultures which include 
biologics. More particularly, this invention relates to micro- 	 isolated populations of cells having specific characteristics. 
organ devices and methods for fabricating and using such 	 These micro-organ cultures have the ability to be maintained 
devices. 	 in culture for relatively long periods of time, as well as the 
2. Discussion of the Related Art 	 30 preservation of an organ micro-architecture which facilitates, 
Testing of pharmaceuticals and biological compounds in 	 for example, cell-cell and cell-matrix interactions analogous 
humans or in animals is not always possible, at least not in the 	 to those in the source organ. 
early stage. Moreover, while in vivo animal studies can pro- 	 These organ models of the related art demonstrate the 
vide data more relevant to human responses, animal tests are 	 advantages of in vitro systems for pharmaceutical or biologi- 
expensive, labor-intensive, and time consuming. Accord-  35 cal compounds testing. However, the related art approaches 
ingly, sometimes decisions need to be made based on in vitro 	 rely on directly placing the cells in the chamber or seeding the 
data. However, extrapolating in vitro data (e.g., cell culture 	 cells and allowing them to grow in the chamber. These 
data) to the in vivo relevant conditions is often difficult. 	 approaches do not always provide reproducible organs. 
Although pharmacokinetic principles can be used to derive 	 Therefore, there remains a need for in vitro organ devices, and 
some conclusions, this approach has limitations due to vari-  40 methods for their preparation, which can mimic the in vivo 
ous reasons. 	 organs or systems in humans and animals. 
For example, cell cultures under traditional assay condi- 
tions may not function in the same ways as cells would in 	 SUMMARY OF INVENTION 
natural settings because the communication and interactions 
between different tissues and organs are absent. In culture, 45 	 In one aspect, embodiments of the present invention relate 
cells are typically grown at the bottom of chambers or wells. 	 to methods for fabricating a micro-organ device. In accor- 
These systems may have unrealistically high liquid-to-cell 
	
dance with one embodiment, the method for fabricating 
ratios. Even if the cells are grown on microcarrier beads, 	 includes providing a microscale support having one or more 
which more closely resemble physiological conditions, they 	 microfluidic channels and one or more micro-chambers for 
still may not mimic physiological conditions accurately 5o housing a micro-organ and printing a micro-organ on the 
enough to provide reliable data. 	 microscale support using a cell suspension in a syringe con- 
Additionally, while controlling the spatial orientation of 	 trolled by a computer-aided tissue engineering system, 
cells having a cell-cell interaction in a co-culture would 	 wherein the cell suspension comprises cells suspended in a 
improve traditional cell culture methods, the cell-cell inter- 	 solution containing a material that functions as a scaffold, and 
actions between different cell types do not always allow 55 wherein the printing is performed with the computer-aided 
proper interactions between different cell types. In humans 	 tissue engineering system according to a pattern. 
and animals, the liver plays an important role in the metabo- 	 In another aspect, embodiments of the present invention 
lism and bioavailability of pharmaceuticals and biological 	 relate to micro-organ devices. A micro-organ device in accor- 
compounds. Consequently, methods of predicting human 	 dance with one embodiment includes at least one micro- 
response from in vitro cell culture assays are complicated, 60 chamber each housing a micro-organ; and at least one microf- 
and systems or devices of the related art designed to replicate 	 luidic channel connected to the micro-chamber, wherein the 
in vivo organs or systems of humans or animals have not 	 micro-organ comprises cells arranged in a configuration that 
performed quite as predicted. 	 includes microscale spacing between portions of the cells to 
Accordingly, scientists with ordinary skill in the art related 
	
facilitate diffusion exchange between the cells and a medium 
to this subject matter have recognized a long-felt need for in 65 supplied from the at least one microfluidic channel. 
vitro organ or system models that can mimic the in vivo 	 Other aspects and advantages of the embodiments 
organs or systems in humans or animals. The related art 	 described herein will become apparent from the following 
US 8,343,740 B2 
3 
description and appended claims, taken in conjunction with 
the accompanying drawings, illustrating the principles of the 
embodiments by way of example only. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a schematic series of processing steps illus-
trating a method for fabricating a microscale support or 
microchip for a micro-organ device in accordance with one 
embodiment of the invention. 
FIG. 2 illustrates possible chemical modification reactions 
of silanol groups on a polydimethyl siloxane (PDMS) micro-
chip. 
FIG. 3 shows a schematic series of processing steps illus-
trating a computer-aided tissue engineering system that can 
be used to bioprint micro-organ devices in accordance with 
one embodiment of the invention. 
FIGS. 4A-4C show three micro-organ devices each having 
different configurations of organ arrays and microfluidic 
channels in accordance with embodiments of the invention. 
FIGS. 5A and 5B show perspective views along the top and 
side, respectively, of a section of a micro-organ, illustrating 
the substructures produced with bioprinting, in accordance 
with one embodiment. 
FIG. 6 is a two-dimensional cross sectional view of a 
three-dimensional micro-organ in accordance with one 
embodiment of the invention. 
FIG. 7 is a perspective view of a three-dimensional micro-
organ device in accordance with one embodiment of the 
invention. 
FIG. 8 shows a schematic diagram of a system comprising 
two micro organs illustrating various microfluidic channels 
and interconnections in accordance with another embodi-
ment. 
FIG. 9 represents a chart of results from an activity assay 
using a liver micro-organ device in accordance with one 
embodiment. 
FIGS. 1OA-10E show examples of various configurations 
and arrays that may be produced for pharmacokinetic studies 
in accordance with another embodiment of the invention. 
DETAILED DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
Exemplary embodiments of the invention will now be 
described with reference to the accompanying figures. Like 
elements or components in the figures are denoted with the 
same reference characters for consistency. 
Before beginning a detailed description of some exemplary 
embodiments of the invention, the meaning of certain terms 
as used herein will be given. 
`Bioprint" or "bioprinting", as used in this description, 
refers to a process of depositing biological materials, such as, 
for example, forming micro-organs using a computer-aided 
tissue engineering (CATE) system to print a micro-organ 
according to a particular design or pattern. These processes 
will be described in more detail below. 
"Microscale" as used herein refers to dimensions no 
greater than 10 cm, preferably no greater than 1 cm. 
"Microchip" as used herein refers to a microscale support 
having one or more microfluidic channels and one or more 
micro-chambers forhousing micro-organs. A microchip typi-
cally has a dimension on the order of a few centimeters. 
"Microfluidic channel" as used herein refers to a channel 
on a microchip. Such channels typically have depth and width 
that are less than a few millimeters, preferably less than 1 mm. 
4 
"Micro-chamber" as used herein refers to a structure (e.g., 
a well or indentation) on a microchip. A micro-chamber typi-
cally has a dimension of no greater than a few cm, preferably 
1 cm or less. A micro-chamber is typically used for housing 
5 cells of a micro-organ. 
"Micro-organ" as used herein refers to cells or tissue bio-
printed on a microchip, typically in a micro-chamber on the 
microchip. 
"Micro-organ device" or "MOD" as used herein refers to a 
io device having at least one micro-organ on a support (such as 
a microchip). 
Embodiments of the invention relate to methods for pro-
ducing or fabricating micro-organ devices (MODS) using a 
bioprinting system for forming cells encapsulated in a struc- 
15 ture and to the micro-organ devices thus produced. The 
micro-organ devices in accordance with the embodiments 
described herein comprise microscale three-dimensional 
(3D) tissue analogs in devices that include microfluidic chan-
nels and chambers. 
20 In accordance with embodiments of the invention, different 
mammalian tissues may be mimicked on such micro-organ 
devices for various applications, such as experimental phar-
maceutical screening for efficacy, adsorption, distribution, 
metabolism, elimination, and toxicity. Thus, these devices 
25 may be used to assess the beneficial and detrimental effects of 
a novel drug after it passes through a given metabolic path-
way. For example, the therapeutic or toxic effects of a drug on 
any cell type in vitro may be assessed in the presence of 
microencapsulated liver cells to take into account the liver- 
3o dependent metabolic modifications of the candidate drug. In 
addition, these devices may be used to evaluate the therapeu-
tic benefits or toxicities of a drug compound. Micro-organ 
devices as disclosed herein can address the need for in vitro 
micro-organs that substantially replicate in vivo structure and 
35 function. 
The micro-organ devices (MODS) in accordance with 
embodiments of the invention may be produced by direct 
bioprinting of specific cells, human or animal, to form micro-
organs in micro-chambers of microchips. Bioprinting pro- 
40 cesses are controllable and can produce reproducible micro-
organs that also mimic the in vivo functions more closely. The 
process of bioprinting may use a technology known as "Com-
puterAided Tissue Engineering" or "CATE" for short, such as 
the technology developed at a laboratory located at Drexel 
45 University in Philadelphia, Pa. CATE is used in the design, 
simulation, and fabrication of cells/tissue to construct micro-
organs. As will be discussed in more detail below, a CATE 
system integrates computer-aided design (CAD) technolo-
gies and modern design and manufacturing in bioengineering 
5o and biomedicine. The CATE system employs a biopolymer 
deposition system that is capable of extruding biopolymer 
solutions and living cells for freeform construction of three-
dimensional tissue scaffolds. The deposition process is bio-
compatible and occurs at room temperature and low pressures 
55 to reduce damage to cells. The CATE system is capable of, 
simultaneously with scaffold construction, depositing con-
trolled amounts of cells, growth factors, or other bioactive 
compounds with precise spatial position to form complex 
cell-seeded three-dimensional tissue constructs. An example 
60 of a CATE system is given in Khalil et al., "Multi-nozzle 
Deposition for Construction of 3D Biopolymer Tissue Scaf-
folds," Rapid Prototyping Journal 2005, Vol. 11, No. 1: 9-17, 
which is hereby incorporated by reference. In accordance 
with other embodiments, the methods of fabricating a micro- 
65 organ device may also comprise forming microchips that 
include microfluidic channels and micro chambers for hous-
ing micro-organs. 
US 8,343,740 B2 
Once the polymer cures, the flexible replica 14 can be 
peeled off the master, leaving the master ready to produce 
another replica . The replica 14 has a pattern complementary 
to the designpattern 12. Once the replica 14 is peeled from the 55 
mold, it is ready for assembly to build a micro-organ device. 
The replica may be cut to proper size with a standard surgical 
blade, and access holes may be punched, if needed, for tubing 
and other conduits to provide access to the micro-organ 
device. For tubing inputs, a needle hole slightly smaller than 60 
the outer diameter of the tubing may be drilled so that 
adequate sealing can be achieved. 
Another useful property of PDMS is that its surface can be 
chemically modified in order to obtain the interfacial proper-
ties of interest. See, Makamba et al., "Surface modification of 65 
poly(dimethylsiloxane) microchannels," Electrophoresis 
2003, 24(21), 3607-19. One suitable method to covalently 
5 
Referring now to FIG. 1, an exemplary method that can be 
used to fabricate a microchip is illustrated in a series of steps. 
As shown in FIG. 1 , a master 10 for making at least one 
microchip comprises a design pattern 12 on a silicon wafer 
11. The master 10 maybe fabricated using techniques that are 
adapted from lithographic techniques commonly used in inte-
grated circuit (IC) chip manufacturing. Examples of using the 
lithographic techniques to fabricate tissue /organ devices can 
be found in U.S. Pat. No. 7,288,405, which is hereby incor-
porated by reference. The design pattern 12, for example, may 
include fluid communication channels or conduits and tissue 
chambers for forming a micro -organ device. A suitable poly-
mer reagent is then poured onto the master 10 and allowed to 
cure, as shown in 13 , to form a replica of the master 10. Any 
suitable polymer reagents may be used for making the replica. 
One suitable example includes a class of compounds gener-
ally referred to as polydimethyl siloxanes (PDMS). Other 
suitable materials may include rubber, polymers, plastic, 
elastomers, and silicone materials (such as Formulations 
RTV 108, RTV 615 or RTV 118 available from General 
Electric, New York, N.Y.). 
As recognized by the skilled artisan, PDMS is a flexible 
elastomeric polymer that is an excellent material for fabrica-
tion of a microfluidic device. For instance , see McDonald et 
al., "Fabrication of microfluidic systems in poly(dimethylsi-
loxane)," Electrophoresis 2000, 21(1), pp. 27-40. Various 
PDMS are commercially available, including Sylgard® 184 
from Dow Corning. Sylgard is a two -part resin system con-
taining vinyl groups (partA) and hydrosiloxane groups (part 
B). Mixing of the two resins under appropriate conditions 
(e.g., by heating at a temperature of 65° C. or higher for 2 
hours) leads to crosslinking (or curing), as illustrated below: 
0 
CH3 	 Catalyst 
HNC/C~ 1 /O 	 + 	 O~ ,g 
i 	 i S ~  
CH3 	 CH3 
Part A 	 Part B 
O 	
C, 
H3 
°', I/~/ 1 o' Si 	 ~ 
CH3 
CH3 
6 
functionalize PDMS is to expose it to an oxygen plasma, 
whereby the surface of Si—CH 3 groups along the PDMS 
backbone are transformed into Si OH groups by the reactive 
oxygen species in the plasma. For example, the PDMS sur- 
5 face may be exposed to O z plasma (100 mW radiofrequency, 
1% 02) for 30 seconds to convert the surface methyl silane 
groups into silanol groups. 
These silanol surfaces can then be transformed with other 
alkoxysiloxanes to yield many different chemistries, some of 
10 which are illustrated in FIG. 2, to facilitate further modifica-
tion or reaction on the replica. The modified PDMS surface, 
which now has modified siloxane groups, can be reacted and 
bonded with another object 15 that contains silanol groups, 
15 such as a glass surface, another PDMS, or the like. In one 
embodiment, bonding of the PDMS microchip to a PDMS-
coated glass slide acting as a substrate is accomplished by 
covering both contact surfaces with titanium tetra (isopro-
poxide). Alternatively, the original PDMS replica 14 from the 
20 polymerization reaction shown above (which contains methyl 
siloxane groups) can be reacted directly with silanol groups 
from the other object 15. With either approach, a microchip 
comprising at least one microfluidic channel and at least one 
micro -chamber can be readily prepared and provided. 
25 In accordance with embodiments of the invention, the cells 
or tissue of interest for mimicking organs may be fabricated 
or printed for placement into at least one micro -chamber of a 
fabricated microchip by a bioprinting system such as a com-
puter-aided tissue engineering (CATE) system 30 of FIG. 3. 
30 System 30 enables computer-aided three -dimensional (3-D) 
printing of biopolymer scaffolds and cell-encapsulated scaf-
folds. The technique for fabrication employs solid freeform 
fabrication (SEE), which are computerized fabrication tech-
niques that can rapidly produce highly complex three -dimen- 
35 sional objects using data from CAD systems and from com-
puter medical imaging equipment such as Magnetic 
Resonance Imaging (MRI) and Computed Tomography (CT) 
scans. The fabricated three -dimensional structures are built 
by reducing CAD designs of particular interest into a group of 
40 sliced two-dimensional layers, to where the prototyping 
material is deposited to build the structure in a layer-by-layer 
process. 
System 30 comprises a computer 31 for controlling the 
placement and movement of one or more syringes 32. The 
45 computer 31 includes at least one central processing unit 
(CPU) for processing a set of program instructions and 
memory for storing at least one CATE program comprising a 
set of program instructions. The at least one CATE program is 
written so as to direct a path of movement and placement of a 
50 robotic-arm to deposit alginate or a cell/alginate mixture from 
a syringe onto a substrate in accordance with a particular 
design or pattern. A CATE program typically includes com-
puter-aided design/engineering/manufacturing (CAD/CAE/ 
CAM) software. The CATE system 30 may comprise a pre-
cision deposition system, which includes the syringes 32 
shown in FIG. 3, along with a robotic arm (not shown) for 
maneuvering the syringes as they "print" onto a particular 
surface. Cells for bioprinting are suspended in a solution 
containing extra-cellular matrix (e.g., collagens) and/or scaf-
fold materials (e.g. alginates ) and loaded in the syringes 32 
for bioprinting the micro -organs 35. In one embodiment, a 
1.5% (w/v) alginate is cross -linked with a calcium chloride 
solution and then injected onto the surface by syringe 32. 
The CATE system can easily print three-dimensional cell-
encapsulated scaffolds on the order of centimeters . Smaller 
dimensions are more of a challenge . In some embodiments, a 
strut width between –125-500 microns (um) was accom- 
US 8,343,740 B2 
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plished. The strut width can be altered by changing the outlet 	 micro-organ device 49 that comprises three micro-organs 41, 
gauge of the syringe and the flow pressure of the solution. 	 43, and 45. The three micro-organs 41, 43, and 45 are inter- 
	
Using the methods and systems described herein and illus- 	 connected via micro-channels or conduits 42. Two curvy 
	
trated in FIGS. 1-3, or a variation thereof, microscale sup- 	 arrows in this figure signify that crosstalk exists between 
ports or microchips are combined with a bioprinting system 5 micro-organs 41 and 43. The communication between the 
	
to fabricate micro-organ devices in accordance with another 	 micro-organ 41 and 43 may be via one or more microfluidic 
	
embodiment. After loading the cells in the micro-chambers 	 channels. The crosstalk may be mediated by the modified 
	
(using the bioprinting process), micro-organ devices (MOD) 	 compound (i.e., metabolite) after conversion by a micro-or- 
	
are obtained. These MODS may have various configurations 	 gan. Alternatively, the crosstalk may be mediated by para- 
of micro-chambers for housing micro-organs interconnected io crine factors, hormones, or other factors that are secreted by 
	
by microfluidic channels to simulate the fluid communica- 	 the cells of the micro-organs in response to a stimulus, e.g., 
	
tions between these organs in vivo. FIGS. 4A-4C illustrate 	 the drug or a metabolite of the drug. 
three embodiments that exemplify such configurations. 	 Note that the examples shown in FIGS. 4A-4C are illustra- 
	
FIG. 4A shows a micro-organ device 40 that comprises a 	 tive only. One of ordinary skill in the art, now having benefit 
single micro-organ 41 in communication with two micro- 15 of this detailed description, would appreciate that embodi- 
	
channels or conduits 42. Device 40 is useful for assessing the 	 ments of the invention are not so limited and that modifica- 
	
effects (beneficial or toxic) on a particular organ and/or the 	 tions or variations from those shown are possible without 
	
mechanisms underlying these effects. For example, the 	 departing from the scope of the invention. For example, the 
	
micro-organ 41 may be a liver or kidney, and the device may 	 micro-channels in these illustrations are shown to have open 
be used to assess the toxicity of various drugs to the liver or 20 ends. Some of these open ends may be interconnected to form 
	
kidney. Further, device 40 may be used to study metabolism 	 loops or circuits. Similarly, the multiple micro-organs shown 
	
of a drug by a particular organ, such as the liver. The liver has 	 in FIG. 4C are arranged (and connected by microfluidic chan- 
	
critical functions in various biological pathways involving 	 nels) in series (i.e., aligned sequentially). Other embodiments 
	
xenobiotics, such as drugs. The functions of a liver may 	 may comprise multiple micro-organs that are connected by 
include converting a pro-drug into an active drug, converting 25 microfluidic channels in "parallel" or in a web. 
	
a drug into a metabolite that may be more active or less active, 	 The microfluidic channels illustrated in the devices of 
	
converting a toxic compound into a soluble form for excretion 	 FIGS. 4A-4C may be on the order of tens to hundreds of 
(detoxification), etc. 	 micrometers (µm) wide, while the micro-chambers that house 
	
Therefore, a micro-organ device having a micro-liver will 	 the micro-organs may have a dimension as large as 1 cm or 
allow a scientist or researcher to use such a device to study 30 more. If the micro-organ were a solid mass of a millimeter 
	
reactions of a biologic or other substance without resorting to 	 (mm) or centimeter (cm) in size, the cells in the interior of the 
	
animal or human tests. In such assays, a drug or test com- 	 micro-organ would not be able to exchange efficiently with 
	
pound may be supplied in a solution from one end of a 	 the media in the microfluidic channels. In general, to ensure 
	
micro-channel 42. The capillary effect and gravity may be 	 effective diffusion exchange, cells are preferably not more 
used to draw the solution into the micro-chamber, where the 35 than 500 µm away from the microfluidic channels. In order to 
	
micro-liver 41 is located, and out the other end of the micro- 	 ensure efficient diffusion exchanges, a micro-organ in accor- 
	
channel 42. If necessary, pumps, pressure or vacuum may also 	 dance with the embodiments may comprise substructures, at 
	
be used to circulate the fluids in the microfluidic channels. 	 least one dimension of which is preferably no larger than 1 
	
The metabolites or modified drugs collected from the outlet 	 millimeter (mm), more preferably less than 500 µm. Such 
may be analyzed to elucidate the liver metabolism pathways 40 micro-organs may be prepared according to the structural 
	
or to study the enzyme activities. In addition, the modified 	 embodiments of FIGS. 5A-8, using the CATE system shown 
	
drugs may be used to test on a target micro-organ, or the like. 	 in FIG. 3. 
	
FIG. 4B shows an alternate micro-organ device 47 com- 	 Referring now to FIG. 5A, a perspective top view of one 
	
prising two micro-organs 41 and 43. The micro-organ device 	 structural embodiment that may be bioprinted is shown so as 
47 further comprises several micro-channels or conduits 42 45 to construct a three-dimensional tissue model of a micro- 
	
for flowing solutions containing compounds to be tested. 	 organ. In particular, two substructures 51 and 52 of a micro- 
	
Device 47 is suitable for studying the interactions between the 	 organ 50 are shown to have been fabricated (bioprinted) in an 
	
micro-organs 41 and 43 or the impacts of the presence of one 	 interdigitated configuration having microscale spacing 
	
micro-organ (e.g., 41) on the other (e.g., 43) when a drug is 	 between one another. The spacing between the two sub-struc- 
administered. 	 50 tures 51 and 52 are designed to form the microfluidic channel 
	
For example, the micro-organ 41 may be a micro-liver, 	 53 for the flow or circulation of media to nourish cells or 
	
while the micro-organ 43 may be the intended target for the 	 tissue. FIG. 5B shows a side view of the substructures of FIG. 
	
drug (e.g., bone). When a drugA is passed throughthe micro- 	 5A, further illustrating the 3-D structure of the tissue model 
	
organ 41 (e.g., liver), it may be converted into a metabolite A', 	 comprising multiple layers or "struts" of scaffolding. 
which maybe more active or les s active than the original drug. 55 Although only three layers of the substructures are shown in 
	
The metabolite A' then acts on the target organ (e.g., the 	 this illustration, a micro-organ may comprise more or less 
	
micro-organ 43). After acting on the target organ, the metabo- 	 layers in other embodiments, as will be discussed with refer- 
	
lite A' may be further metabolized to a new metabolite A". 	 ence to FIGS. 6-8. In this particular example, each layer is 
	
With such a device, phannacokinetic and pharmacodynamic 	 about 200 µm thick, and the spacing between the substruc- 
studies would be performed under conditions more closely 60 tures forming the channel 53 is about 20 µm. This particular 
	
related to in vivo conditions than using a cell culture or a 	 microscale thickness and microscale spacing enables cells at 
single organ device. 	 the interior of the micro-organ to efficiently exchange with 
	
A micro-organ device may comprise any number of micro- 	 the media (by diffusion) in the micro-channels. 
	
organs. With a proper design of micro-chambers and inter- 	 The interdigitated substructures and the multi-layer stack- 
connecting micro-channels, the various interactions between 65 ing maybe bioprinted using the CATE system shown in FIG. 
	
the organs in a human may be replicated or at least mimicked. 	 3. When bioprinting is used, cells of the micro-organ are 
	
FIG. 4C illustrates another embodiment, which shows a 	 suspended in a solution containing one or more extra-cellular 
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matrix or scaffold materials. The solution is put in a syringe 
that is controlled by a computer for "printing" the micro-
organ onto a surface, such as a microchip, according to a 
particular design. The printing process may be performed one 
layer at a time until the desired number of layers of the 5 
substructure is achieved. 
The interdigitated configuration of the substructures 51 
and 52 and the microscale spacing between them that forms 
the microfluidic channels 53 are also shown in a top view in 
FIG. 6. This top view shows a sectionof an entire micro -organ io 
60 comprising repeated layers (interdigitated folds) of sub-
structures 51, 52, and the microfluidic channel 53 to achieve 
a particular overall dimension of interest (e.g., 1 cm). 
The two-dimensional (2D) top view shown in FIG. 6 rep-
resents a layer (section) of a 3D micro-organ. FIG. 7 shows a 15 
perspective view of a 3D micro-organ 71 that comprises a 
plurality of the 2D sections shown in FIG. 6. FIG. 7 shows that 
the 3D micro-organ 71 is disposed in a micro-chamber of a 
micro-organ device (MOD) 70. The micro-organ device 
(MOD) 70 also comprises a microfluidic channel or conduit 20 
72 with an inlet 72a and an outlet 72b. As noted above, the 
MOD 70 may be made of any suitable materials, such as 
PDMS. The MOD 70 is shown to be supported on a substrate 
or chip 75, which may be a silicon wafer, glass, glass coated 
with PDMS, or plastic and have a dimension on the order of 25 
one to several centimeters. 
As shown in FIGS. 4B and 4C, a micro-organ device 
(MOD) of the invention may include more than one micro-
organ, which may be operatively interconnected to one 
another by one or more microfluidic channels. FIG. 8 shows 30 
a system 80 in accordance with one embodiment of the inven-
tion that comprises two micro-organs 81, 82 connected by a 
network of microfluidic channels 83. The network of microf-
luidic channels 83 is shown to include various valves (de-
noted by the reference character V), reservoirs (R), pumps 35 
(P), and detectors (D). 
In the example shown in FIG. 8, the chip footprint may be 
in the range of 1-5 cmx1-5 cm. The fluidic channels may be 
about 25-50 µm deep and about 100-350 µm wide. The fluidic 
channels in the electrophoresis chamber or section may be 40 
smaller, e.g., about 50 µm wide. The valves (V) may be 
controlled by pneumatic control lines, which serve to actuate 
the valves for controlling fluid flow and fluid pumping. The 
pneumatic control lines may be 10 µm deep and 200 µm wide, 
for example. Note that these dimensions are for illustration of 45 
this particular example. One of ordinary skill in the art, now 
having benefit of this description, would appreciate that a 
MOD in accordance with other embodiments may also be 
prepared in other sizes and dimensions. 
The pumps shown in FIG. 8 may be peristaltic pumps or 50 
syringe pumps. The detector may be any suitable detector 
(optical, UV, fluorescence, IR, laser, etc.) for detecting or 
assessing drug conversion or metabolite analysis. The system 
shown in FIG. 8 also includes an electrophoresis separation 
and detection section, which may be used to analyze any 55 
metabolites or converted drugs. 
The methods for bioprinting of cells in accordance with 
embodiments of the invention do not adversely impact the 
viability of the cells. In one example, using mouse hepato-
cytes(ATCC, CRL-2254) encapsulated in alginate hydrogels, 60 
it was found that the resultant micro-organ retained 79% 
viable cells. A micro-organ of liver cells thus prepared was 
found to produce a higher amount of urea than the same 
number of hepatocytes cultured on tissue culture plastic, sug-
gesting that the cells in the MOD are healthier. 65 
More importantly, micro-organ devices constructed in 
accordance with these methods are found to be able to per- 
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form functions that mimic, or are similar to, the in vivo 
functions of the corresponding organ. For example, FIG. 9 is 
a chart of results from an experiment concerning the conver-
sion of 7-ethoxy-4-trifluoromethylcoumarin (EFC) to 7-hy-
droxy-4-trifluoromethylcoumarin (HFC) by a liver micro-
organ device in accordance with one embodiment of the 
invention. EFC is converted to HFC by liver cytochromes 
P450 (P450s). Liver cytochrome P450 enzymes are involved 
in drug metabolism. EFC has weak or no fluorescence, while 
HFC has strong fluorescence. Therefore, this system provides 
a convenient assay for the drug metabolizing enzymes in the 
liver. Liver MODS in accordance with an exemplary embodi-
ment are found to convert EFC to HFC at rates ranging from 
1 to 10 picomoles/hr/104 cells. Results shown in FIG. 9 indi-
cate the MODS can have functions like those of its corre-
sponding in vivo organs. Thus, MODS can be used to mimic 
such organs for the study of drug metabolism or other phar-
macokinetic applications. 
In particular, at least one embodiment of the micro-organ-
device (MOD) may be designed to mimic the complex in vivo 
microenvironment of human or animal cells and tissue, 
including proper inter-communications between different 
organs, by constructing a three-dimensional tissue model to 
be housed within a microchip that replicates the in vivo 
micro-organ structure, extra-cellular matrix composition and 
architecture, and the in vivo fluid flow. One or more micro-
organs may be created by suspending human or animal mam-
malian cells in a specific soluble extra-cellular matrix (ECM) 
and scaffold and printing three-dimensional micro-organs 
with a computer aided tissue engineering (CATE) system. 
The micro-organs may be directly printed and arrayed as 
single or multi-organs on at least one microchip or micro-
fabricated microfluidic device. The microchip houses the 
micro-organs to form a micro-organ device. Fluids are then 
circulated through the micro-organs to maintain viability and 
to deliver specific soluble factors and molecules. A system, 
such as the system 80 of FIG. 8, may be constructed to control 
and direct the perfusion of cell culture medium and specific 
soluble factors such as investigative drugs and chemicals 
using algorithms related to the law of mass conservation. 
In one embodiment, system 80 may be constructed to con-
trol and direct perfusion by equations related to the conser-
vation of mass. First, the rate of metabolism in the tissue 
analog (or MOD), represented by the variable R m, is a product 
of the volume of in-flow to the tissue analog from which the 
drug would be entirely removed in unit time, represented by 
the variable CL, and the drug concentration entering the tis-
sue analog, as represented by the variable C, This relation 
may be denoted by the equation: 
R_ -CL-C l . 
The tissue analog of this embodiment may be represented as 
comprising the following additional set of variables: 
Q—circulating rate of perfusate; 
C2 —drug concentration exiting tissue analog; 
R—constant rate of continuous infusion; and, 
D=total amount of drug in the medium. 
Further, given that 
V, _
_Tt 
i~ 
_ 
- QC, + QCz  + R, 	 (t) 
Vz dT 	 (2) z = -QCz + QC, - CLC, ,  
